Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (VRNA)
NASDAQ:VRNA
VRNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.51 - $104.99
Previous CloseN/A
Volume658.49K
Average Volume (3M)4.61M
Market Cap
$8.91B
Enterprise Value$8.50B
Total Cash (Recent Filing)$401.42M
Total Debt (Recent Filing)$2.13M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Jul 31, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding85,132,000
10 Day Avg. Volume11,339,236
30 Day Avg. Volume4,612,189
Financial Highlights & Ratios
PEG Ratio-7.32
Price to Book (P/B)39.27
Price to Sales (P/S)0.00
P/FCF Ratio-73.97
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue50.52
Enterprise Value/Gross Profit75.74
Enterprise Value/Ebitda-14.22
Forecast
1Y Price Target
$106.22Price Target Upside1.41% Upside
Rating ConsensusHold
Number of Analyst Covering11
Verona Pharma News
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionOhtuvayre is a good fit for Merck, strengthening Merck's growing cardio-pulmonary pipeline and portfolio with its dual bronchodilation and anti-inflammation mechanisms.
Product Approval And GrowthOhtuvayre, a first-in-class PDE3 and PDE4 dual inhibitor, has shown strong revenue growth since its launch, indicating fast adoption among physicians and patients.
Strategic AcquisitionMerck's acquisition of Verona Pharma for $107/ADS is seen as a justifiable value, pricing in its multibillion-dollar potential and expanding Merck's portfolio in cardiopulmonary disease treatments.
Bears Say
Cost And Income ImpactIncreased costs have been modeled, resulting in a reduction in net income for 2025.
Market CompetitionDespite inclusion in the GOLD treatment guidelines for COPD, Ohtuvayre is only briefly mentioned with weak language, indicating limited recognition in the competitive landscape.
Stock Rating DowngradeIn the wake of the deal announcement, the rating was downgraded to Neutral from the prior Buy.
Ownership Overview
36.45% Insiders
14.13% Mutual Funds
0.10% Other Institutional Investors
48.74% Public Companies and Individual Investors
VRNA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was $18.51 and its highest was $104.99 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Verona Pharma Plc’s market cap is $8.91B.
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Jul 31, 2025 which is in 14 days.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on Apr 29, 2025. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.056.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is 0.03.
How many shares outstanding does Verona Pharma Plc have?
Verona Pharma Plc has 85,132,000 shares outstanding.
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went up 6.378%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Currently, no hedge funds are holding shares in VRNA
Verona Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$106.22 (1.41% Upside)
$106.22 (1.41% Upside)
Blogger Sentiment
Neutral
VRNA Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.9%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
387.30%
12-Months-Change
Fundamentals
Return on Equity
-72.73%
Trailing 12-Months
Asset Growth
81.41%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma (VRNA) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases. The company is primarily involved in the research and development of novel compounds that target unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Verona Pharma's lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, designed to improve lung function and reduce inflammation.
VRNA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Verona Pharma plc reflected a positive sentiment overall, driven by the successful launch and strong sales of O2VERE, significant financial achievements, and robust progress in global regulatory and intellectual property strategies. Despite some financial losses and high expenses, the company's strong cash position and strategic financing provide a solid foundation for continued growth.Read More>VRNA Stock 12 Month Forecast
Average Price Target
$106.22
▲(1.41%Upside)